Market Closed -
Nasdaq
04:00:00 2024-05-01 pm EDT
|
5-day change
|
1st Jan Change
|
1.21
USD
|
+1.68%
|
|
+12.04%
|
+52.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
126.2
|
834.3
|
585.8
|
239.2
|
180.1
|
309.2
|
-
|
-
|
Enterprise Value (EV)
1 |
126.2
|
834.3
|
585.8
|
239.2
|
180.1
|
309.2
|
309.2
|
309.2
|
P/E ratio
|
-0.91
x
|
-5.99
x
|
-3.68
x
|
-1.43
x
|
-1.47
x
|
-4.17
x
|
-3.32
x
|
-3.36
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
112
x
|
211
x
|
95.3
x
|
8.81
x
|
2.99
x
|
3.63
x
|
5.1
x
|
5.05
x
|
EV / Revenue
|
112
x
|
211
x
|
95.3
x
|
8.81
x
|
2.99
x
|
3.63
x
|
5.1
x
|
5.05
x
|
EV / EBITDA
|
-
|
-
|
-
|
-1.51
x
|
-1.39
x
|
-4.89
x
|
-3.1
x
|
-
|
EV / FCF
|
-1,106,046
x
|
-14,915,568
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
105,166
|
154,779
|
156,204
|
163,829
|
227,122
|
255,562
|
-
|
-
|
Reference price
2 |
1.200
|
5.390
|
3.750
|
1.460
|
0.7930
|
1.210
|
1.210
|
1.210
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/14/22
|
3/6/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.122
|
3.958
|
6.149
|
27.15
|
60.28
|
85.11
|
60.64
|
61.28
|
EBITDA
1 |
-
|
-
|
-
|
-157.9
|
-129.9
|
-63.3
|
-99.7
|
-
|
EBIT
1 |
-139.8
|
-133.4
|
-162.2
|
-164
|
-139.7
|
-97.49
|
-136.1
|
-150.6
|
Operating Margin
|
-12,457.22%
|
-3,370.52%
|
-2,638.58%
|
-603.97%
|
-231.82%
|
-114.55%
|
-224.51%
|
-245.79%
|
Earnings before Tax (EBT)
1 |
-136.9
|
-129.9
|
-157.3
|
-163
|
-112.5
|
-92.16
|
-142.2
|
-147.8
|
Net income
1 |
-137.2
|
-130.1
|
-158.1
|
-165.5
|
-113.9
|
-91.11
|
-132.3
|
-141
|
Net margin
|
-12,225.04%
|
-3,286.81%
|
-2,570.99%
|
-609.46%
|
-188.9%
|
-107.05%
|
-218.14%
|
-230.13%
|
EPS
2 |
-1.320
|
-0.9000
|
-1.020
|
-1.020
|
-0.5400
|
-0.2900
|
-0.3650
|
-0.3600
|
Free Cash Flow
|
-114.1
|
-55.93
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-10,169.25%
|
-1,413.14%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/14/22
|
3/6/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.203
|
1.417
|
3.575
|
5.538
|
7.007
|
11.03
|
47.6
|
5.13
|
7.319
|
0.231
|
17.07
|
27.73
|
12.4
|
27.93
|
15.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-42.18
|
-42.86
|
-49.98
|
-43.75
|
-42.99
|
-27.24
|
1.656
|
-44.91
|
-46.63
|
-49.86
|
-28.92
|
-16.03
|
-34.4
|
-18.18
|
-32.4
|
Operating Margin
|
-3,506.32%
|
-3,024.98%
|
-1,398.07%
|
-790.03%
|
-613.53%
|
-247.03%
|
3.48%
|
-875.4%
|
-637.15%
|
-21,582.68%
|
-169.46%
|
-57.8%
|
-277.45%
|
-65.08%
|
-203.77%
|
Earnings before Tax (EBT)
1 |
-42.19
|
-38.65
|
-49.63
|
-44.05
|
-41.02
|
-28.26
|
1.661
|
-20.71
|
-44.91
|
-48.57
|
-27.57
|
-14.89
|
-33.01
|
-16.73
|
-32.3
|
Net income
1 |
-42.4
|
-38.86
|
-50.26
|
-44.52
|
-41.42
|
-29.25
|
1.036
|
-21.39
|
-45.6
|
-47.92
|
-22.68
|
-17.27
|
-32.57
|
-18.64
|
-32.3
|
Net margin
|
-3,524.61%
|
-2,742.27%
|
-1,406.01%
|
-803.9%
|
-591.14%
|
-265.23%
|
2.18%
|
-416.94%
|
-623.05%
|
-20,743.29%
|
-132.86%
|
-62.27%
|
-262.66%
|
-66.71%
|
-203.14%
|
EPS
2 |
-0.3000
|
-0.2400
|
-0.3000
|
-0.0500
|
-0.0400
|
-0.1800
|
-
|
-0.1200
|
-0.0300
|
-0.2400
|
-0.0750
|
-0.0725
|
-0.0750
|
-0.0725
|
-0.1400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/14/22
|
5/9/22
|
8/4/22
|
11/8/22
|
3/6/23
|
5/12/23
|
8/9/23
|
11/8/23
|
3/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-114
|
-55.9
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.59
|
2.34
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
141.89%
|
59.15%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/14/22
|
3/6/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
1.21
USD Average target price
3.5
USD Spread / Average Target +189.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +52.59% | 304M | | -1.17% | 102B | | +2.87% | 96.09B | | +2.13% | 22.28B | | -14.77% | 21.4B | | -8.79% | 18.14B | | -39.98% | 17.02B | | -13.21% | 16.09B | | +8.55% | 13.83B | | +35.75% | 11.97B |
Bio Therapeutic Drugs
|